FARMINGDALE, N.Y., March 19, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (DepYmed or the Company) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many...
FARMINGDALE, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (DepYmed or the Company) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
FARMINGDALE, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (DepYmed or the Company) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
FARMINGDALE, N.Y., Oct. 03, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (œDepYmed or the œCompany) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
FARMINGDALE, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (œDepYmed or the œCompany) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
FARMINGDALE, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (œDepYmed or the œCompany) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
FARGDALE, N.Y., June 15, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (DepYmed or the Company) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
FARMINGDALE, New York, May 31, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (œDepYmed or the œCompany) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
FARMINGDALE, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology based upon targeting the protein tyrosine phosphatase (PTP) family of enzymes. Today, DepYmed announces that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its lead clinical candidate, a small molecule PTP1B inhibitor for the treatment of patients with Rett Syndrome (RTT).
FARMINGDALE, N.Y., May 23, 2022 (GLOBE NEWSWIRE) -- DepYmed Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...